Evidence map›Paper›PMID 40736178›Full record

ArticleInvestigative ophthalmology & visual science2025

Epac1 Inhibits Orbital Fibroblast Activation to Ameliorate Thyroid-Associated Orbitopathy-Like Features Through the JAK/STAT Signaling Pathway.

Rong Liu, Xin Xin, Shunguo Ma, Jinmin Guo, Chenmian Wu, Xin Qi, Ban Luo

Abstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Gypenosides attenuate HAmerican journal of translational research · 2026
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rong LiuDepartment of Ophthalmology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Xin XinDepartment of Obstetrics and Gynecology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Shunguo MaDepartment of Ophthalmology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Jinmin GuoDepartment of Ophthalmology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Chenmian WuDepartment of Ophthalmology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Xin QiDepartment of Ophthalmology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Ban LuoDepartment of Ophthalmology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Orbital fibroblast (OF) activation plays an important role in thyroid-associated orbitopathy (TAO) development. Epac1, as a cyclic adenosine monophosphate (cAMP) effector, has been recognized as a pivotal mediator of the anti-fibrosis properties of cAMP. This study investigated the role and mechanisms of Epac1 in OF activation. Methods: Clinical orbital samples were collected from patients with TAO and normal healthy volunteers, and a TAO mouse model was established using adenovirus expressing the human TSHR A subunit (Ad-TSHR), which was evaluated for histopathological features and detected for Epac1 and vimentin expression levels. Clinical TAO samples- (TAO OFs) and healthy people-derived OFs (normal OFs) were isolated and identified using immunofluorescent (IF) staining. Healthy and TAO OFs were transfected with Epac1-overexpressing plasmid (Epac1) for Epac1 overexpression or sh-Epac1 plasmid for Epac1 knockdown, treated with TGFβ1, and then examined for cell phenotypes and the expression level of Epac1 and fibrosis-related markers (α-SMA, fibronectin, and collagens). Furthermore, adeno-associated virus (AAV) overexpressing Epac1 (AAV-Epac1) was injected into TAO mouse orbital tissues to investigate the anti-fibrotic effects of Epac1 on TGFβ1-stimulated OFs in vivo. Moreover, the phosphorylation of STAT3 in the TGFβ1-stimulated TAO OFs and TAO mice model was investigated. The JAK/STAT signaling inhibitor Stattic was used to explore the involvement of the JAK/STAT signaling in the functions of Epac1. Results: Both clinical TAO samples and the TAO mouse model demonstrated significantly changed histopathology, reduced Epac1 expression, and increased vimentin level. TGFβ1 stimulation significantly facilitated cell viability and migration of normal OFs and TAO OFs, and elevated α-SMA, fibronectin, vimentin, collagen I, and collagen III expression levels. However, Epac1 overexpression in OFs could notably attenuate these pro-fibrosis effects of TGFβ1 on both normal and TAO OFs, shown as inhibiting cell viability and migration and decreasing expression of fibrotic markers. Whereas, Epac1 knockdown aggravated TGFβ1-induced fibrosis. In vivo, Epac1 overexpression also improved TAO-like symptoms in TAO model mice. Mechanically, Epac1 overexpression inhibited STAT3 phosphorylation in vitro and in vivo. Stattic effectively attenuated the effects of Epac1 knockdown on TGFβ1-treated TAO OFs. Conclusions: Epac1 was a critical regulator of fibrotic and inflammatory processes in TAO through mediating the JAK/STAT signaling pathway.

Indexed as

FibroblastsGene Expression RegulationGraves OphthalmopathyGuanine Nucleotide Exchange FactorsJanus KinasesOrbitAdultAnimalsCells, CulturedDisease Models, AnimalFemaleHumansMaleMiceMice, Inbred C57BLMiddle AgedEpac protein, mouseGuanine Nucleotide Exchange FactorsJanus KinasesSTAT3 Transcription Factor

Identifiers

PMID40736178
PMCPMC12315924

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.